ArticlePharmaceutics2022
Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Silica nanoparticles as advanced platforms for nucleic acid delivery.Materials today. Bio · 2026Review
- Strategies for overcoming multiple barriers of oral administration of protein and peptide therapeutics.Materials today. Bio · 2026Review
- Mesoporous silica nanoparticles in glioblastoma: smart nano-platforms for targeted therapy and precision diagnosis.3 Biotech · 2026Review
- Correction: MacCuaig et al. Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery.Pharmaceutics · 2026Article
- Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model.Frontiers in bioengineering and biotechnology · 2026Article
- Comprehensive Review of Mesoporous Carbon and Mesoporous Silica in Poorly Soluble Drug Delivery: Insights into Drug Loading, Dissolution, Stability, and Pharmacological Performance.International journal of nanomedicine · 2026Review
- A Systematic Review of Advanced Drug Delivery Systems: Engineering Strategies, Barrier Penetration, and Clinical Progress (2016-April 2025).Pharmaceutics · 2025Review
- Nanotoxicity of Porous Silica Nanoparticles: Physicochemical Properties and Mechanistic Cellular Endpoints.Nanomaterials (Basel, Switzerland) · 2025Review
- pH-Responsive Liposomes for Targeted Detection of Pancreatic Adenocarcinoma Using MSOT.Chemical & biomedical imaging · 2025Article
- Encapsulated citrus peel essential oil in pegylated mesoporous silica nanoparticles for postharvest control of Botrytis cinerea in strawberry.Scientific reports · 2025Article
- Mesoporous Silica Nanoparticles as Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Nano-oncology revisited: Insights on precise therapeutic advances and challenges in tumor.Fundamental research · 2025Review
- Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Cationized Cellulose Materials: Enhancing Surface Adsorption Properties Towards Synthetic and Natural Dyes.Polymers · 2024Review
- Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management.Nanomedicine (London, England) · 2024Review
- Strategies to Regulate the Degradation and Clearance of Mesoporous Silica Nanoparticles: A Review.International journal of nanomedicine · 2024Review
- Nanoparticles systemically biodistribute to regenerating skeletal muscle in DMD.Journal of nanobiotechnology · 2023Article
- Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery.Pharmaceutics · 2023Review
- Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy.Pharmaceutics · 2022Review
- Silica nanoparticles in medicine: overcoming pathologies through advanced drug delivery, diagnostics, and therapeutic strategies.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Nanoparticles are popular tools utilized to selectively deliver drugs and contrast agents for identification and treatment of disease. To determine the usefulness and translational potential of mesoporous silica nanoparticles (MSNs), further evaluations of toxicity are required. MSNs are among the most utilized nano-delivery systems due to ease of synthesis, pore structure, and functionalization. This study aims to elucidate toxicity as a result of intravenous injection of 25 nm MSNs coated with chitosan (C) or polyethylene glycol (PEG) in mice. Following acute and chronic injections, blood was evaluated for standard blood chemistry and complete blood count analyses. Blood chemistry results primarily indicated that no abnormalities were present following acute or chronic injections of MSNs, or C/PEG-coated MSNs. After four weekly administered treatments, vital organs showed minor exacerbation of pre-existing lesions in the 35KPEG-MSN and moderate exacerbation of pre-existing lesions in uncoated MSN and 2KPEG-MSN treatment groups. In contrast, C-MSN treatment groups had minimal changes compared to controls. This study suggests 25 nm MSNs coated with chitosan should elicit minimal toxicity when administered as either single or multiple intravenous injections, but MSNs coated with PEG, especially 2KPEG may exacerbate pre-existing vascular conditions. Further studies should evaluate varying sizes and types of nanoparticles to provide a better overall understanding on the relation between nanoparticles and in vivo toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.